Problem

Cancer care is highly heterogeneous, yet treatment is often approached as if cancer were a single disease and patients are forced to navigate a one-size-fits-all system. The painful information gap is especially acute when a patient must evaluate high-stakes treatment choices, understand unfamiliar medical language, identify testing gaps, or find a relevant clinical trial. Radical’s main use case is effectively an always-available, data-rich second opinion: helping a cancer patient determine whether they may be missing a better treatment option or trial.

The economics are compelling because the conventional alternative—a comprehensive review by another top oncologist—can cost about $3,000 out of pocket and take weeks or months, while still reflecting one clinician’s opinion and typically ending after a single appointment. Radical positions its service as a faster, lower-cost way to expand access to expert-level oncology knowledge, while keeping the treating oncologist in the decision loop.

Product / Service

Radical Health provides a direct-to-consumer AI oncology report and ongoing navigation service. A patient describes their cancer type, stage, and treatment history, then connects medical records; the system analyzes clinical notes, pathology and radiology reports, labs, genetics, and other records. It compares the case with more than 11 million patient journeys, approximately 20,000 treatment options, 5.3 million research papers, and 48,800 active cancer trials, producing a personalized report in about 24 hours.

The product compares treatment paths, explains the diagnosis in plain language, matches clinical trials, and continues monitoring for newly opened trials and relevant research. It also includes a dedicated oncology nurse and an AI navigator, with a seven-day free trial followed by pricing of $110 per month. Radical says reports are informational and educational rather than a replacement for the treating oncologist, and that reports are checked by both software and domain experts.

Market

Radical competes at the intersection of oncology artificial intelligence, precision-medicine decision support, clinical-trial matching, and patient navigation. Its closest competitive set includes provider-facing oncology platforms such as Flatiron Assist, which prioritizes evidence-based treatment and research at the point of care, and Tempus, which offers AI-driven precision-oncology insights. COTA is another adjacent competitor in oncology real-world data and AI analytics. Radical’s differentiation is its general-purpose oncology model and patient-facing delivery: it packages large-scale clinical and research evidence into a consumer-accessible report and ongoing support rather than selling only an enterprise workflow to providers.

As of August 1, 2026, Radical is an early-stage company rather than a proven scaled operator. It emerged from stealth in December 2025 with a $5 million pre-seed round led by Khosla Ventures, joined Mayo Clinic Platform_Accelerate’s AI-startup cohort, and reports technical validation including a perfect USMLE score. The service is publicly accessible through a free trial and paid subscription, but the reviewed public materials disclose no customer count, revenue, or evidence of established commercial scale; the best-supported characterization is early commercial availability with traction demonstrated primarily through funding, partnerships, product launch, and technical validation.